[Skip to Content]
[Skip to Content Landing]
Article
February 1969

Comparison of Two Further Attenuated Live Measles-Virus Vaccines

Author Affiliations

New York; Winnipeg, Canada; New York
From the Department of Pediatrics, New York University School of Medicine, New York (Drs. Krugman and Giles); and the University of Manitoba, Winnipeg, Canada (Drs. Constantinidis and Medovy). Doctor Giles is a New York City Health Research Council Awardee.

Am J Dis Child. 1969;117(2):137-138. doi:10.1001/archpedi.1969.02100030139002
Abstract

TWO strains of live attenuated measles-virus vaccine have been licensed for use in the United States, the Edmonston B strain in March 1963 and the Schwarz further attenuated strain in February 1965. Both the Edmonston B and the Schwarz strain vaccines have been highly immunogenic and protective against measles.1 However, the incidence of high fever and rash has been significantly less following inoculation of the further attenuated vaccine.

A recent report by Hilleman et a12 described the development and evaluation of a new further attenuated vaccine, designated by the name of "Moraten." The present study was undertaken to compare Moraten with the Schwarz strain in regard to clinical reactions and immunogenic effect.

The studies were conducted in Winnipeg, Canada and at the Willowbrook State School, Staten Island, NY. The Winnipeg study was carried out in institutionalized children at the St. Amant Home and in home-dwelling children of the Children's Aid

×